The TP53 p.R337H Germline Variant and Breast Cancer: Prevalence from a Cohort Study and Structured Literature Review
Archives of Breast Cancer · 25.07.2026 · 13 (3) · 302-309
DOI: 10.32768/abc.8035914726-841 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Archives of Breast Cancer, online erschienen am 25.07.2026. Verfasst von Paula Stephanie Duarte Oliveira und 3 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: The TP53 p.R337H germline variant is a Brazilian founder variant associated with Li-Fraumeni syndrome and increased cancer susceptibility. Its prevalence among breast cancer (BC) patients remains incompletely characterized. The objective of this study is to evaluate the prevalence of the TP53 p.R337H germline variant among breast cancer (BC) patients through a cohort study and structured literature review. METHODS: One hundred BC patients from Hospital Universitário Antonio Pedro were interviewed and tested for the p.R337H variant using Sanger sequencing. A structured literature review was also conducted following PRISMA 2020 recommendations, searching PubMed, LILACS and SciELO for studies published between 1997 and 2025. Studies reporting zero detected cases were included to reduce selection bias. Due to heterogeneity among studies, no formal meta-analysis was performed and prevalence was reported descriptively. RESULTS: Of the 100 patients tested in our study, none had the variant (0.0%; 95% CI: 0.00-3.62%). Of 46 identified records, 17 studies met the inclusion criteria. A total of 173 carriers were identified among 8,221 patients in the reviewed literature. Including our cohort, the combined sample totaled 8,321 patients, with a crude aggregated prevalence of 2.08% (95% CI 1.79-2.41%). Higher prevalence was observed in patients diagnosed at ≤ 45 years and in malignant phyllodes tumors, while lower or absent prevalence was observed in unselected populations. CONCLUSION: The prevalence of the p.R337H variant among breast cancer patients varied across studies, according to age at diagnosis, patient selection criteria and geographic region. Larger multicenter studies are needed to better define its role in breast cancer risk assessment.
Zitieren
APA
Oliveira, P. S. D., André, L. S. P., Silva, A. V. D., & Aguiar-Alves, F. (2026). The TP53 p.R337H Germline Variant and Breast Cancer: Prevalence from a Cohort Study and Structured Literature Review. Archives of Breast Cancer, 13(3), 302-309. https://doi.org/10.32768/abc.8035914726-841
Vancouver
Oliveira PSD, André LSP, Silva AVD, Aguiar-Alves F. The TP53 p.R337H Germline Variant and Breast Cancer: Prevalence from a Cohort Study and Structured Literature Review. Archives of Breast Cancer. 2026;13(3):302-309. doi:10.32768/abc.8035914726-841
BibTeX
@article{Oliveira2026,
author = {Oliveira, Paula Stephanie Duarte and André, Lialyz Soares Pereira and Silva, André Vallejo Da and Aguiar-Alves, Fábio},
title = {The TP53 p.R337H Germline Variant and Breast Cancer: Prevalence from a Cohort Study and Structured Literature Review},
journal = {Archives of Breast Cancer},
year = {2026},
volume = {13},
number = {3},
pages = {302--309},
doi = {10.32768/abc.8035914726-841}
}
EUVIMED